key: cord-0986266-6oqzshr0
authors: Pelleau, S.; Woudenberg, T.; Rosado, J.; Donnadieu, F.; Garcia, L.; Obadia, T.; Gardais, S.; Elgharbawy, Y.; Velay, A.; Gonzalez, M.; Nizou, J.-Y.; Khelil, N.; Zannis, K.; Cockram, C.; Merkling, S.; Meola, A.; Kerneis, S.; Terrier, B.; de Seze, J.; Planas, D.; Schwartz, O.; Dejardin, F.; Petres, S.; von Platen, C.; Arowas, L.; Perrin de Facci, L.; Duffy, D.; Ni Cheallaigh, C.; Conlon, N.; Townsend, L.; Auerswald, H.; Backovic, M.; Hoen, B.; Fontanet, A.; Mueller, I.; Fafi-Kremer, S.; Bruel, T.; White, M. T.
title: Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins
date: 2021-03-08
journal: nan
DOI: 10.1101/2021.03.04.21252532
sha: a4e8f47828e1c11e8128b006611e86e1ebe5299f
doc_id: 986266
cord_uid: 6oqzshr0

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a complex antibody response that varies by orders of magnitude between individuals and over time. Waning antibody levels lead to reduced sensitivity of serological diagnostic tests over time. This undermines the utility of serological surveillance as the SARS-CoV-2 pandemic progresses into its second year. Here we develop a multiplex serological test for measuring antibodies of three isotypes (IgG, IgM, IgA) to five SARS-CoV-2 antigens (Spike (S), receptor binding domain (RBD), Nucleocapsid (N), Spike subunit 2, Membrane-Envelope fusion) and the Spike proteins of four seasonal coronaviruses. We measure antibody responses in several cohorts of French and Irish hospitalized patients and healthcare workers followed for up to eleven months after symptom onset. The data are analysed with a mathematical model of antibody kinetics to quantify the duration of antibody responses accounting for inter-individual variation. One year after symptoms, we estimate that 36% (95% range: 11%, 94%) of anti-S IgG remains, 31% (9%, 89%) anti-RBD IgG remains, and 7% (1%, 31%) anti-N IgG remains. Antibodies of the IgM isotype waned more rapidly, with 9% (2%, 32%) anti-RBD IgM remaining after one year. Antibodies of the IgA isotype also waned rapidly, with 10% (3%, 38%) anti-RBD IgA remaining after one year. Quantitative measurements of antibody responses were used to train machine learning algorithms for classification of previous infection and estimation of time since infection. The resulting diagnostic test classified previous infections with 99% specificity and 98% (95% confidence interval: 94%, 99%) sensitivity, with no evidence for declining sensitivity over the time scale considered. The diagnostic test also provided accurate classification of time since infection into intervals of 0 - 3 months, 3 - 6 months, and 6 - 12 months. Finally, we present a computational method for serological reconstruction of past SARS-CoV-2 transmission using the data from this test when applied to samples from a single cross-sectional sero-prevalence survey.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 , has led to widespread morbidity and mortality since its emergence. The response to the SARS-CoV-2 pandemic is critically dependent on surveillance data, most notably numbers of COVID-19 associated hospital admissions and deaths recorded through health systems surveillance, as well as numbers of cases confirmed SARS-CoV-2 positive by PCR-based testing 1 . Other tools are providing crucial complementary information, for example genomic surveillance has been key to tracking the emergence of novel SARS-CoV-2 variants 2 . Serology, based on the detection of antibodies induced by previous infection with SARS-CoV-2, represents another category of surveillance information 3, 4 . Appropriately designed sero-prevalence studies can provide estimates of the proportion of a population who have been previously infected. Although no substitute for health systems surveillance, sero-prevalence studies have the advantage of accounting for asymptomatic cases, and symptomatic individuals who do not present to health systems. Sero-prevalence studies also provide information on the status of SARS-CoV-2 epidemics in situations where record keeping by health systems is not possible 5 .

Infection with SARS-CoV-2 induces diverse humoral and cellular immune responses 6 . Humoral immunity includes antibodies of several immunoglobulin isotypes targeting SARS-CoV-2 proteins, most notably Spike (S) and Nucleocapsid (N). The concentration of antibodies in blood varies substantially between individuals, and with time since infection 6, 7, 8, 9, 10, 11 . Studies of the duration of immunity to a range of coronaviruses demonstrated that antibodies remain detectable six years after infection, but continue to wane 12 . Longitudinal follow-up of individuals infected with SARS-CoV-2 indicates a pattern of waning of antibody responses consistent with other coronaviruses 13, 14 . Within the first three months, antibody levels boost sharply and wane rapidly. Over a longer interval of eight months, antibody levels wane more slowly 6 . These observations can be explained by the bi-phasic nature of antibody kinetics 15 . In the first three months, antibodies are predominantly generated by short-lived plasma cells in secondary lymphoid organs. The long-term response is dominated by antibodies from long-lived plasma cells in the bone marrow. This pattern of bi-phasic waning is observed for infection-and vaccine-induced antibody responses to a wide range of pathogens 16, 17, 18, 19 .

Initial concerns that waning antibody responses would lead to reduced sensitivity of SARS-CoV-2 serological diagnostics over time have unfortunately been confirmed 20 . Using self-administered lateral flow diagnostic tests, a sero-prevalence study of 365,000 adults after the first epidemic wave in the UK observed significantly declining sero-prevalence during July to September 2020 4 . Using a laboratory-based assay for measuring anti-N IgG antibodies, a sero-prevalence survey of blood donors from the Brazilian city of Manaus estimated that 26% of the population had previously been infected 21 .

Application of a statistical adjustment to account for antibody waning led to an increased estimate of 76% previously infected. As the pandemic progresses, this problem of declining sensitivity of serological diagnostics is likely to get worse, potentially undermining the utility of sero-prevalence studies.

Serological diagnostics typically classify a sample as positive if a measured antibody level is greater than a defined cutoff.

Analysis of quantitative rather than binary antibody levels provides additional information, for example antibody levels . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ;  https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint are associated with time since infection, symptom severity, and sex 22 . However, large variation in antibody levels between individuals prevents this from having predictive value: detected antibodies could be from a recent infection, or due to immunological memory of an infection that cleared a year ago. This limitation has recently been overcome for a range of pathogens through the combination of multiplex assays and classification algorithms. Using machine learning algorithms to analyse quantitative antibody responses to multiple antigens, the time since previous infection can be estimated for Plasmodium falciparum malaria 23,24 , P. vivax malaria 25 , and cholera 26 .

In this study, we use multiplex assays to measure antibodies to SARS-CoV-2 in health care workers and hospitalized patients followed for up to eleven months after infection, and apply mathematical models to characterize antibody kinetics in the first year following infection. Classification algorithms were developed that minimize the reduction in the sensitivity of serological tests over time, in addition to estimating time since previous infection from a single blood sample.

Finally, we present a method for serological reconstruction of past SARS-CoV-2 transmission using samples from a single cross-sectional survey.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021 In April 2020, our team implemented a study of the sero-prevalence of SARS-CoV-2 in healthcare workers from Institut Mutualiste Montsouris, a hospital in Paris. Serum samples were collected from 769 healthcare workers, and tested with our multiplex assay (Appendix Figure 1 ). Healthcare workers who tested sero-positive in April 2020 were invited to present a second sample in January 2021. In total we obtained follow-up samples from 29 healthcare workers. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

We set up a 9-plex bead-based assay allowing simultaneous detection of antibody responses to five SARS-CoV-2 antigens and four seasonal coronaviruses (Spike proteins of NL63, 229E, HKU1, OC43) in 1µL serum or plasma samples that were heat-inactivated at 56°C for 30 minutes. SARS-CoV-2 antigens were from Spike (whole trimeric Spike (S), its Receptor Binding Domain (RBD) and Spike subunit 2 (S2)), nucleocapsid protein (N) and a Membrane-Envelope fusion protein (ME). ME and S2 antigens were purchased from Native Antigen, Oxford, UK and all other antigens were produced as recombinant proteins at Institut Pasteur. The mass of proteins coupled on beads was optimized to generate a log-linear standard curve with a pool of 27 positive sera prepared from RT-qPCR-confirmed SARS-CoV-2 patients. We measured the levels of IgG, IgA and IgM of each sample in three separate assays. Briefly, serum was incubated with mixed antigen-coupled beads for 30 minutes at a 1/200 final dilution for IgG or 1/400 for IgA and IgM. Secondary antibodies conjugated to R-phycoerythrin (Jackson Immunoresearch) were used at 1/120, 1/200 or 1/400 for detection of specific IgG, IgA and IgM respectively. All dilutions and cycles of washing steps were done in phosphate buffer saline supplemented with 1% bovine serum albumin and 0.05% (v/v) Tween-20. On each assay plate, two blanks (only beads, no serum) were included to control for background signal as well as a standard curve prepared from two-fold serial dilutions (1/50 to 1/102,400) of a pool of positive controls. Plates were read using a Luminex® MAGPIX® system and the median fluorescence intensity (MFI) was used for analysis. A 5-parameter logistic curve was used to convert MFI to relative antibody unit (RAU), relative to the standard curve performed on the same plate to account for inter-assay variations.

The data from our multiplex assay was compared against data from two different neutralization assays with live virus using a subset of serum samples. Firstly, we implemented an S-Fuse assay as described elsewhere 32 . Neutralization activity was measured as the reciprocal dilution required to obtain a 50% reduction in neutralization (IC50). Secondly, we implemented a foci reduction neutralization test (FRNT) based on the detection of neutralizing antibodies directed against SARS-CoV-2.

This assay was performed under BSL-3 conditions as it facilitates infection of African green monkey kidney cells (VeroE6; ATCC CRL-1586) with live-virus of a Cambodian SARS-CoV-2 isolate (GISAID: EPI_ISL_411902). Infection is visualized 14-16h after inoculation by staining of infected cells with a SARS-CoV-2 specific antibody (# ABIN1030641), targeting the S2 subunit of the viral spike protein. Neutralizing antibody titers are expressed as the reciprocal serum/plasma dilution that induces 50% reduction of infection (FRNT50) and is calculated by log probit regression analysis.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Measurements of antibodies of three isotypes (IgG, IgM, IgA) to multiple SARS-CoV-2 antigens were used to create a training dataset. Samples where the time post symptom onset was ≤ 14 days or unknown were excluded. In total we had 407 samples from pre-pandemic negative controls and 1402 positive samples. In a first step, a Random Forests binary classification algorithm was developed. A threshold corresponding to 99% specificity was selected. In a second step, a Random Forests multiway classification algorithm was developed for categorizing samples into four classes: (i) negative;

(ii) infected ≤ 3 months ago; (iii) infected 3 -6 months ago; and (iv) infected 6 -12 months ago. The algorithm was calibrated to have 99% specificity for correctly classifying negative samples. Positive samples were then classified according to the maximum number of votes. Uncertainty in classification performance was assessed via 1000-fold crossvalidation with a training set comprising two thirds of the data and a disjoint testing set comprising a third of the data.

Classification algorithms were implemented in R (version 3.4.3).

Imperfect diagnostic sensitivity causes a downwards bias in sero-prevalence estimates, whereas imperfect specificity causes an upwards bias in seroprevalence estimates. This bias can be corrected for using a Rogan-Gladen estimator, with incorporation of cross-validated uncertainty 34 . Multiway classification algorithms provide estimates of the proportion of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint a population infected during different time intervals. These estimates are subject to biases which can be adjusted for using a multivariate extension of the Rogan-Gladen estimator described in the Statistical Appendix. Informed written consent was obtained from all participants or their next of kin in accordance with the Declaration of Helsinki.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint

Antibody responses of three isotypes (IgG, IgM, IgA) to nine coronavirus antigens were measured in 407 pre-pandemic serum samples, and 1402 serum samples from individuals with previous SARS-CoV-2 infection. 961/1402 of the positive samples were from individuals with SARS-CoV-2 infection confirmed by PCR-based testing with available data on time post symptoms. Figure 1 presents the IgG, IgM and IgA antibody responses to SARS-CoV-2 S, RBD, and N measured over time.

Appendix Figures 2 and 3 presents the antibody responses to S2, ME, and the Spike proteins of the four human seasonal coronaviruses. Notably there is substantial inter-individual variation in antibody responses, with antibody levels varying by orders of magnitude between individuals. As a measure of functional immunity, we applied live virus neutralizing assays to a subset of samples. Substantial variation in neutralizing activity between individuals and over time (Appendix Figure   4 ). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint

Our data on measured SARS-CoV-2 antibody responses was supplemented with data from six other longitudinal studies of the SARS-CoV-2 antibody response, and one longitudinal study of the SARS-CoV-1 antibody response. Appendix Figure   5 provides a comparison of the measured antibody responses between the eight studies. The data have been rescaled so that the average antibody response for each study equals one at day 14 after symptom onset. In addition to the large inter-individual variation, there is notable variation in antibody levels between studies. For example, the large dynamic range in the study by Iyer et al 8 , reveals the boosting and subsequent decay of anti-S IgG antibodies in the first two months post infection, a phenomenon that is missed by assays without a comparably high upper limit of detection.

A mathematical model of antibody kinetics was simultaneously fitted to data from all eight studies. Appendix Figure 6 provides an overview of the fit of the model to the data. Figure 2a provides example fits to data from one individual from each of the eight studies. Figure 2b provides model predictions of the percentage antibody level remaining over the first two years post infection, where 100% is assumed to be the antibody response at day 14 following symptom onset. There are considerable differences in the pattern of waning between isotypes and between antigens. Table 2 summarises the duration of the antibody response. One year following symptom onset, we estimate that 36% (95% range: 11%, 94%) anti-S IgG remains, 31% (9%, 89%) anti-RBD IgG remains, and 7% (1%, 31%) anti-N IgG remains. The uncertainty represents the considerable degree of inter-individual variation in the duration of the antibody responses. Antibodies of the IgM isotype waned more rapidly, with 6% (0%, 27%) anti-S IgM remaining after one year, 9% (2%, 32%) anti-RBD IgM remaining after one year, and 15% (4%, 50%) anti-N IgM remaining after one year. Antibodies of the IgA isotype also waned rapidly, with 18% (4%, 67%) anti-S IgA remaining after one year, 10% (3%, 38%) anti-RBD IgA remaining after one year, and 3% (0%, 13%) anti-N IgA remaining after one year. We also observed comparable reductions in titres for viral neutralization over time (Appendix Figure 4) , although the small number of samples prevented application of our model.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint

Using a dataset on measured IgG, IgM and IgA antibody levels from pre-pandemic negative controls and samples from individuals with SARS-CoV-2 infection confirmed by PCR-based testing and followed for up to eleven months after symptom onset, Random Forests binary classification algorithms were trained to identify individuals with previous SARS-CoV-2 infection (Appendix Figures 7 and 8 ). Next, a Random Forests multi-way classification was trained to simultaneously identify previous infection and estimate the time since infection (Figure 3 ). The diagnostic test identified samples from individuals with previous SARS-CoV-2 infection with 99% specificity and 98% (95% confidence interval: 94%, 99%) sensitivity ( Figure 3a) . The diagnostic test classified samples from individuals infected within the previous 3 months ( Figure   3b ). Notably, it was easier to distinguish recent infections (<3 months) from older infections (6 -12 months), compared to infections that occurred 3 -6 months ago. There was limited statistical signal to distinguish between infections that occurred 3 -6 months ago, and older infections occurring more than 6 months ago (Figure 3c) . A breakdown of classification performance by time since infection is provided in Figure 3D . The diagnostic test accurately classifies samples of all categories, with the exception of samples from individuals infected 3 -6 months ago. Many of these samples were incorrectly classified in the neighbouring infection categories of 0 -3 months or 6 -12 months. There is a substantial degree of misclassification of samples with time since infection 3 -6 months ago. This is due to the temporal imbalance in the training data.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint

When applied to samples from a cross-sectional sero-prevalence survey, a diagnostic test capable of estimating time since infection can provide a serological reconstruction of past SARS-CoV-2 epidemics. Figure 4 presents four simulated epidemics where 1,000 individuals were sampled, and 40% were previously infected. A range of scenarios were simulated, including a recent epidemic wave, an older epidemic wave, a double wave epidemic, and constant transmission. The algorithm was able to accurately reconstruct all epidemic profiles. For example, in the recent wave scenario 60% of the population were negative and the model estimated 59.8% (95% CI: 59.3%, 61.4%); 35.8% were infected 0 -3 months ago and the model estimated 35.5% (95% CI: 25.7%, 40.3%); 4.2% were infected 3 -6 months ago and the model estimated 4.2% (95% CI: 0.0%, 14.4%); and 0% were infected 6 -12 months ago and the model estimated 0% (95% CI: 0.0%, 3.3%). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint

Infection with SARS-CoV-2 induces a complex, diverse immune response, that varies by orders of magnitude between individuals, and changes over time. This diversity is a challenge to immunologists and vaccinologists, but presents an opportunity to diagnostic developers armed with multiplex assays and machine learning algorithms. By quantifying the kinetics of different components of the humoral immune response, it is possible to provide classification of previous infection that minimizes the reduction of diagnostic sensitivity over time, and also allows estimation of the time since infection.

Based on data from a range of studies with up to eleven months follow up after symptom onset, we estimate that 31% (95% CrI: 9%, 89%) of anti-RBD IgG antibody levels remain one year after infection. Antibodies of other isotypes waned more rapidly, with 9% (95% CrI: 2%, 32%) of anti-RBD IgM antibody levels remaining after one year, and 10% (95% CrI: 3%, 38%) of anti-RBD IgA antibody levels remaining after one year. There was considerable variation in kinetic profiles between different SARS-CoV-2 antigens, with 7% (95% CrI: 1%, 31%) of anti-N IgG antibody levels remaining after one year. Although the determinants of the duration of antigen-specific antibody responses remain poorly understood 22 , the diversity in patterns of antibody kinetics can be quantified using epidemiological studies, yielding valuable information for serological diagnostics.

The majority of commercially available serological tests classify individuals as having previous SARS-CoV-2 infection if a measured antibody response is greater than a defined cutoff 35 . Instead of reducing a complex antibody response to a binary data point, a mode detailed serological signature based on quantitative measurements of multiple antibody responses provides two notable advantages 20 . Firstly, the reduction in diagnostic sensitivity associated with waning antibodies is minimized -no reduction in diagnostic sensitivity over the eleven months of follow up was observed.

Secondly, the time since previous infection can be estimated providing valuable additional epidemiological information.

For the current assay, previous infections were categorised into intervals of 0 -3 months, 3 -6 months, and 6 -12 months.

More precise classification is possible in theory, but this must be balanced against the statistical signal. For example, there was little statistical signal to discriminate between infections that occurred 6 -9 months ago, versus infections that occurred 9 -12 months ago. It is anticipated that further improvements to the assay such as the incorporation of new antigens, more training samples with a range of time since infection, and better algorithms will lead to improvements in accuracy.

Existing sero-prevalence studies estimate the proportion of a population previously infected with SARS-CoV-2. The addition of a diagnostic tool capable of estimating time since infection allows for the serological reconstruction of past transmission trends. Thus, using samples from a sero-prevalence study collected at a single time point, we can discriminate between a scenario of constant SARS-CoV-2 transmission and a scenario where transmission occurs in distinct epidemic waves. This diagnostic technology has a range of possible applications. For countries that experienced double wave SARS-CoV-2 epidemics, it has been challenging to quantify the relative magnitude of these waves due to the time required to . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The widespread introduction of SARS-CoV-2 vaccines will lead to vaccine-induced immunity in many individuals. The majority of vaccines against SARS-CoV-2 target the Spike protein's RBD. As our diagnostic assay and algorithms include Spike and RBD antigens, serum samples from vaccinated individuals would likely be classified as positive. However, by measuring antibody responses to Nucleocapsid, Membrane, Envelope, and other viral proteins 37 it will be possible to modify the diagnostic test to provide three-way classification: negative; previously infected; or vaccinated. Identification of individuals who have been both infected and vaccinated will be challenging. Having classified an individual as previously infected or vaccinated, the diagnostic algorithm can then be used to estimate time since infection or time since vaccination. Such an approach could contribute to efforts to measure population-level immunity to SARS-CoV-2, whether induced by infection or vaccination.

There are several limitations to this study. Estimates of the duration of antibody responses are based on data from multiple studies, each using a unique immunoassay 6, 7, 8, 9, 10, 11, 12 . Every immunoassay may differ in terms of background reactivity, cross-reactivity with other pathogens, protein formulation, dynamic range and reproducibility. We believe that the benefit of drawing on multiple data sources outweighs the benefit of having a smaller more homogeneous database, especially since the mathematical model of antibody kinetics is sufficiently flexible to incorporate data from multiple assays. Our selection of a mechanistic mathematical model of antibody kinetics is a potential limitation. The model is based on a mechanistic understanding of the immunological processes underlying the generation and persistence of antibodies, and imposes a flexible functional form on how antibody levels change over time. Although this approach has been validated in a range of applications 16, 17, 18, 19 , there will be instances where the model fails to capture the true pattern of antibody kinetics, for example in immune-deficient individuals. An advantage of a mechanistic model versus a non-parametric statistical model is the ability to make projections forward in time. We have provided predictions up to two years following infection, for example by estimating that 16% (5%, 48%) of anti-RBD IgG antibodies remain after two years. There is a risk to providing predictions beyond the timescale of the data, but these predictions can be easily falsified via continued longitudinal studies.

The diagnostic assay is not exempt from the challenges of antibody waning. Although no reductions in diagnostic sensitivity over time were observed, reduced sensitivity will likely be observed as we analyse additional samples over longer durations of follow up. There are substantial challenges in providing estimates of time since infection. Although the approach can reliably reconstruct the distribution of infection times across a population, there will be substantial uncertainty in estimates of the time since previous infection for individual samples.

Sero-prevalence studies are playing a critical role in monitoring the progress of the SARS-CoV-2 pandemic. In the early stages of the pandemic, immunoassays had the advantage of measuring high antibody levels in the initial months after infection. As the pandemic progresses, sero-prevalence will become more challenging to accurately measure due to . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint waning antibody responses and increased vaccine-induced immunity. Multiplex assays and algorithms accounting for how antibody levels change over time may be an important tool for ensuring the ongoing utility of sero-surveillance.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Data and code will be made available online following peer review of the article. In the meantime, requests for data or code should be made to the corresponding author. Figure 1 : Application of multiplex assay to a sero-prevalence study in Institut Mutualiste Montsouris hospital in Paris. (A) Cross-validated receiver operating characteristic (ROC) curve showing the diagnostic performance of a multiplex assay for measuring IgG, IgM and IgA antibodies to SARS-CoV-2 antigens. This assay can achieve 98% sensitivity and 99% specificity. (B) Measured sero-prevalence in 769 healthcare workers across a range of diagnostic specificities. (C) Sero-prevalence adjusted with a Rogan-Gladen estimator. It can be shown that accuracy is maximized by selecting high specificity 20 . At 99% specificity, this gives an estimated sero-prevalence of 8.7% (95 CI: 6.7%, 11.0%). In all panels, the green line represents the median prediction and the shaded regions represent the 95% confidence intervals.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint

A bead-based multiplex Luminex assay was used to measure antibodies of multiple isotypes (IgG, IgM, IgA) to multiple antigens in serum samples from individuals with PCRpositive SARS-CoV-2 infection and pre-pandemic negative controls. Shown here are the antibody responses to the SARS-CoV-2 Spike subunit 2 (S2) and Membrane-Envelope fusion (ME) antigens, and the Spike protein of the OC43 human seasonal coronavirus.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint Appendix Figure 5 : Data on SARS-Cov-2 antibody kinetics. Overview of data used for fitting mathematical model of antibody kinetics from seven studies with longitudinal follow-up of individuals after infection with SARS-CoV-2, and one study with longitudinal followup after infection with SARS-CoV-1. Note that the study by Tang et al. measured antibodies to SARS-CoV-1 over six years of follow-up, hence the cut in x-axis. There were considerable differences in the immunoassays used for each study, notably variation in antigens and different platforms. For each study, the data has been normalized so that at day 14 post symptom onset, the expected antibody level equals 1. Measured antibody levels from negative controls are shown in the left portion of the plot.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint Appendix Figure 6 : Modelled SARS-CoV-2 antibody kinetics. Overview of the fit of a mathematical model of antibody kinetics to data from seven studies with longitudinal follow-up of individuals after infection with SARS-CoV-2, and one study with longitudinal followup after infection with SARS-CoV-1. For each study, the data has been normalized so that at day 14 post symptom onset, the expected antibody level equals 1. Measured antibody levels from negative controls are shown in the left portion of the plot. Predicted antibody kinetics are shown for a period of 2 years. The solid line represents the median predicted antibody level for each study.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint

Several teams have conducted studies of the duration of the antibody response against SARS-CoV-2 with varying durations of follow up. Our data analyses the duration of the SARS-CoV-2 antibody response over approximately eleven months. To better characterize the antibody kinetics over different time scales, we supplemented our database with data from six published studies on SARS-CoV-2 antibody kinetics. These data are summarized in Appendix Table 1 . In addition to the studies on SARS-CoV-2 antibody kinetics, we also included data from one study of SARS-CoV-1 antibody kinetics in individuals with six years follow-up 12 .

Appendix is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint (IgG, IgM or IgA) at rate g, and r is the rate of decay of antibody molecules. Assuming Ps(0) = Pl(0) = 0 and A(0) = Abg, these equations can be solved analytically to give:

δ is the time after symptom onset when antibody levels start to increase. B0 is the number of B cells, and g is the rate at which they secrete antibodies. As g and B0 are not both identifiable without detailed and invasive experiments (e.g. bone marrow aspirates to measure antigen-specific plasma cells), we estimate = 0 . If r is the decay rate of antibody molecules, then we define = log (2) to be the half-life of antibody molecules. Similarly, we define = log (2) and = log (2) .

Note that this model of antibody kinetics follows the formulation outlined in White et al. 33 

The model was fitted to longitudinal antibody level measurements from all participants. Mixed effects methods were used 

For individual n from study m we have data on observed antibody levels , = { 1 , … , } at times , = { 1 , … , }.

We denote , = ( , , , ) to be the vector of data for individual n from study m. For individual n from study m, the . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint parameters , = ( , , , , , , , , , , , , , ) are estimated. The model predicted antibody levels will be { ( 1 ), ( 2 ), … , ( )}. We assume log-Normally distributed measurement error such that the difference between ( ) and ( ( )) is Normally distributed with variance ) , ( , | , )

As the proportion of the ASCs that are long-lived must be bounded by 0 and 1, the individual-level parameters ρ m,n are assumed to be drawn from logit-Normal distributions. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 8, 2021. ;  ( | ) = ∏ , ∈ ( | )

The model was fitted to the data using Markov Chain Monte Carlo (MCMC) methods. A three stage parameter update regimen was utilised with a Metropolis-within-Gibbs sampler with sequential updating of individual-level parameters, population-level parameters, and observational variance parameters. A′ indicates an attempted update. where ,0 and ,0 parameterise the Normal prior distribution on the mean, and k and θ parameterise the Gamma prior distribution on the precision (inverse standard deviation). is the individual-level parameter i in individual n.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. where ,0 and ,0 parameterise the Normal prior distribution on the mean, and k and θ parameterise the Gamma prior distribution on the precision (inverse standard deviation).

 For each study m, update the observational variance parameter , ′  Calculate updated total likelihood ( ′| )and the updated prior probability density ( ′)

 Accept the parameter update with probability (1,

The MCMC algorithm was implemented in C++ complied in Microsoft Visual Studio. The covariance of the multivariate-Normal proposal distributions for Metropolis-Hastings updates were adaptively tuned using the estimated posterior distributions during a burn-in phase of 1 million MCMC iterations. The magnitude of the proposed step size was calibrated using a Robbins-Munro algorithm to achieve an acceptance rate of approximately 23%. The total number of MCMC iterations was 10,000,000. The effective number of iterations was calculated using the effectiveSize routine in the R library coda and the effective size was checked to be > 1,000 for all parameters. The statistical inference procedure was repeated twice to allow for assessment of chain convergence using Gelman-Rubin convergence diagnostics Rc. For all populationlevel chains, we ensure Rc < 1.05. For all individual-level chains, we ensure Rc < 1.1.

A ROC curve obtained from a training data set consisting of positive and negative samples is described by a sequence of Following the Rogan-Gladen estimator approach, this equation can be rearranged to give an adjusted estimate of true seroprevalence:

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 8, 2021. ;  ( ) = + ( ) − 1 ( ) + ( ) − 1 with ( ) = 0 if < 1 − ( ). Both and ( ) are summarized as medians with 95% ranges.

Define α K as a K-way classification algorithm that can classify a sample into one of K categories. Let C0 be the category for a sample from an individual not previously infected with SARS-CoV-2. Let Ck be the category for individuals previously infected with SARS-CoV-2 in one of K -1 time intervals defined by (0, t1, …, tK-1). α K can be any of a range of algorithms from Random Forests, Support Vector Machines, or ordinal logistic regression. α K can be trained on a data set, with classification performance assessed using N-fold cross-validation. For a serum sample, let Pk denote the classification score (analogous to a probability) that this sample belongs to category k.

Given a vector of classification scores Pk, we can assign a serum sample to a category. A frequently used approach is to select k according to the maximum of Pk. In order to retain better control over diagnostic specificity, we select an alternative two step approach:

 if P0 ≥ γ99 then the sample is classified as negative  if P0 < γ99 then the sample is classified into category k according to the maximum of P1, …, PK-1

Here γ99 is selected based on the training data to ensure a target specificity of 99%. The classification performance of this approach can be assessed using a confusion matrix Cij defined by the proportion of samples of category i classified as category j. For the example with K = 4 explored in more detail here, we define three intervals: 0 -3 months; 3 -6 months;

6 -12 months.

Following the approach of the Rogan-Gladen estimator, define M to be the vector of measured prevalences in each of the K categories. An estimator of the true sero-prevalence is provided by E(T) = C -1 * M where C -1 is the inverse of the confusion matrix. Depending on the values of the confusion matrix, this approach may have Tk < 0. In this instance we assign Tk = 0 and transfer the predictions proportionally to the other categories.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.04.21252532 doi: medRxiv preprint

Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors

INSERM, IRM UMR_S 1109

Service de Pathologies Professionnelles, F-67091

Insect-Virus Interactions Unit, Department of Virology and CNRS UMR

Epidemiology and Modelling of Bacterial Escape to Antimicrobials Unit, Department of Global Health

Estimating the burden of SARS-CoV-2 in France

An action plan for pan-European defence against new SARS-CoV-2 variants

Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance

Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. medRxiv

Seroprevalence of anti-SARS-CoV-2 IgG antibodies among truck drivers and assistants in Kenya

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study

The time course of the immune response to experimental coronavirus infection of man

MERS-CoV antibody responses 1 year after symptom onset, South Korea

Humoral immunity due to long-lived plasma cells

Linking the seroresponse to infection to within-host heterogeneity in antibody production

Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis A virus

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial